Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of “Hold” from Brokerages

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been assigned a consensus recommendation of “Hold” from the five analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $9.40.

RXRX has been the topic of several research reports. JPMorgan Chase & Co. raised shares of Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $10.00 to $11.00 in a research note on Wednesday, December 17th. UBS Group set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Morgan Stanley set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th. Bank of America cut their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, January 22nd.

Recursion Pharmaceuticals Price Performance

RXRX opened at $3.11 on Friday. The company has a current ratio of 5.50, a quick ratio of 5.50 and a debt-to-equity ratio of 0.01. The company has a market cap of $1.64 billion, a price-to-earnings ratio of -2.10 and a beta of 1.02. The stock has a fifty day simple moving average of $3.61 and a two-hundred day simple moving average of $4.43. Recursion Pharmaceuticals has a 12-month low of $2.80 and a 12-month high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Wednesday, February 25th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.07. The firm had revenue of $35.54 million for the quarter, compared to analysts’ expectations of $24.56 million. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on equity of 63.98%. The company’s quarterly revenue was up 671.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.53) EPS. Research analysts predict that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In other news, CFO Ben R. Taylor sold 7,956 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $3.39, for a total value of $26,970.84. Following the sale, the chief financial officer directly owned 1,180,318 shares of the company’s stock, valued at approximately $4,001,278.02. This represents a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Blake Borgeson sold 220,000 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $4.20, for a total value of $924,000.00. Following the transaction, the director owned 6,429,863 shares of the company’s stock, valued at $27,005,424.60. The trade was a 3.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 489,680 shares of company stock valued at $2,046,321. Insiders own 8.43% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. TD Waterhouse Canada Inc. grew its holdings in shares of Recursion Pharmaceuticals by 64.1% during the second quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock valued at $29,000 after buying an additional 2,200 shares during the last quarter. International Assets Investment Management LLC bought a new stake in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $31,000. Sequoia Financial Advisors LLC purchased a new position in Recursion Pharmaceuticals in the 4th quarter worth approximately $41,000. Allworth Financial LP lifted its position in Recursion Pharmaceuticals by 85.6% in the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock valued at $47,000 after acquiring an additional 4,403 shares in the last quarter. Finally, IFP Advisors Inc lifted its position in Recursion Pharmaceuticals by 81.5% in the 3rd quarter. IFP Advisors Inc now owns 10,355 shares of the company’s stock valued at $51,000 after acquiring an additional 4,650 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.